Trial Profile

A Phase I, Open Label, Study to Assess Safety, Tolerability, Biodistribution, Radiation Dosimetry and SPECT/CT Imaging Characteristics of Intravenous 111In-IPN01087 in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma or Colorectal Cancer.

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 02 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zalsenertant-tetraxetan (Primary)
Indications Adenocarcinoma; Colorectal cancer; Pancreatic cancer; Pancreatic ductal carcinoma
Focus Adverse reactions
Sponsors Ipsen

24 Mar 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.(the study was stopped due to Business decision not related to any safety or tolerability concern).
29 Jan 2021 Planned initiation date changed from 5 Jan 2021 to 12 Mar 2021.
17 Dec 2020 Planned initiation date changed from 3 Dec 2020 to 5 Jan 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com